A Review of NEPA, a Novel Fixed Antiemetic Combination with the Potential for Enhancing Guideline Adherence and Improving Control of Chemotherapy-Induced Nausea and Vomiting

Table 4

Efficacy of NEPA in gender/age emetic risk groups.

Overall (0–120 h) CR; % of patients	NEPA + DEX	Oral PALO + DEX	% Difference (95% CI)
Females <55 years; (high risk); ()	80.0	69.0	11.0 (−1.0; 23.0)
Females ≥55 years; (moderate risk); ()	84.5	69.4	15.0 (3.9; 26.2)
Males <55 years; (low risk); ()	89.7	71.4	18.3 (7.6; 29.0)
Males ≥55 years; (lowest risk); ()	92.8	81.1	11.7 (5.0; 18.5)

NEPA: netupitant/palonosetron; PALO: palonosetron; CR: complete response; CI: confidence interval.